Case 1:22-cv-00252-MSG Document 59-7 Filed 03/02/23 Page 1 of 5 PageID #: 1054
`
`Exhibit 7
`
`

`

`Case 1:22-cv-00252-MSG Document 59-7 Filed 03/02/23 Page 2 of 5 PageID #: 1055
`
`1
`NEWS RELEASE
`Moderna Announces New Supply Contract With The
`U.S. Government For An Initial 66 Million Doses Of A
`Moderna Bivalent Covid-19 Booster Vaccine With
`Options For U.S. Government To Purchase Up To An
`Additional 234 Million Doses
`7/29/2022
`New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022;
`additional options, if exercised, may raise total to 300 million doses
`CAMBRIDGE, MA / ACCESSWIRE / July 29, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company
`pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has
`secured 66 million doses of a Moderna COVID-19 vaccine booster candidate, mRNA-1273.222, a bivalent booster
`candidate containing Spikevax™ plus the Omicron BA.4/5 strain mRNA.
`The contract includes an award of up to $1.74 billion for the manufacture and delivery of 66 million doses of mRNA-
`1273.222, as well as options to purchase up to an additional 234 million doses of COVID-19 vaccine booster
`candidates from Moderna.
`"We are pleased to extend our successful collaboration with the U.S. government," said Stéphane Bancel, Chief
`Executive Ocer of Moderna. "Moderna's mRNA platform is enabling us to rapidly create mRNA-1273.222, a
`bivalent vaccine that specically targets Omicron subvariants BA.4 and BA.5, the most prevalent variants of concern
`in the U.S. today. We remain fully committed to leveraging our innovative technology platform to oer tailored
`vaccines that help protect communities against COVID-19."
`

`

`Case 1:22-cv-00252-MSG Document 59-7 Filed 03/02/23 Page 3 of 5 PageID #: 1056
`
`2
`On July 11, 2022, Moderna announced that it is advancing two bivalent candidates for the fall based on dierent
`population health security strategies in dierent countries. mRNA-1273.222 contains the BA.4/5 Omicron strain and
`is being developed in accordance with recent FDA recommendations, while mRNA-1273.214 contains the BA.1
`Omicron strain, which may be of benet as noted by the WHO. These updated bivalent vaccines, if authorized, may
`oer higher, broader and more durable protection against COVID-19.
`The contract announced today is supported by federal funds from the U.S. Department of Health and Human
`Services, Administration for Strategic Preparedness and Response (ASPR), Biomedical Advanced Research and
`Development Authority (BARDA) and awarded by the Department of Defense Joint Program Executive Oce for
`Chemical, Biological, Radiological Nuclear Defense (JPEO-CBRND) and the Army Contracting Command under
`contract number W58P05-22-C-0017.
`INDICATION (U.S.)
`SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease
`2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of
`age and older.
`IMPORTANT SAFETY INFORMATION
`Do not administer to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any
`component of the vaccine.
`Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event
`an acute anaphylactic reaction occurs following administration of the vaccine.
`Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following
`the second dose. The observed risk is higher among males under 40 years of age than among females and older
`males. The observed risk is highest in males 18 through 24 years of age.
`Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in
`place to avoid injury from fainting.
`Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished
`response to the vaccine.
`The vaccine may not protect all vaccine recipients.
`

`

`Case 1:22-cv-00252-MSG Document 59-7 Filed 03/02/23 Page 4 of 5 PageID #: 1057
`
`3
`Adverse reactions reported in clinical trials following administration of the vaccine include pain at the injection site,
`fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the
`injection site, and erythema at the injection site, and rash.
`The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse
`Event Reporting System (VAERS) online at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967.
`Please see the SPIKEVAX Full Prescribing Information. For information regarding authorized emergency uses of the
`Moderna COVID-19 Vaccine, please see the EUA Fact Sheet.
`About Moderna
`In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs
`in the eld of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics
`across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle
`formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at
`scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial
`collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval
`of one of the earliest and most eective vaccines against the COVID-19 pandemic.
`Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology
`and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases,
`immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a
`top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
`Forward Looking Statements
`This press release contains forward-looking statements within the meaning of the Private Securities Litigation
`Reform Act of 1995, as amended, including regarding: the Company's development of bivalent vaccine candidates
`against COVID-19 (mRNA-1273.214 and mRNA-1273.222); the U.S. government's purchase of doses of mRNA-
`1273.222 and potential for further option exercises for the purchase of this vaccine; and the potential for bivalent
`vaccines to oer higher, broader and more durable protection against COVID-19. The forward-looking statements in
`this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-
`looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which
`are beyond Moderna's control and which could cause actual results to dier materially from those expressed or
`implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks
`and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-
`K led with the U.S. Securities and Exchange Commission (SEC) and in subsequent lings made by Moderna with
`

`

`Case 1:22-cv-00252-MSG Document 59-7 Filed 03/02/23 Page 5 of 5 PageID #: 1058
`
`4
`the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims
`any intention or responsibility for updating or revising any forward-looking statements contained in this press
`release in the event of new information, future developments or otherwise. These forward-looking statements are
`based on Moderna's current expectations and speak only as of the date of this press release.
`Moderna Contacts
`Media:
`
`Elise Meyer
`
`Senior Director, Corporate Communications
`
`617-852-7041
`
`Elise.Meyer@modernatx.com
`Investors:
`
`Lavina Talukdar
`
`Senior Vice President & Head of Investor Relations
`
`617-209-5834
`
`Lavina.Talukdar@modernatx.com
`SOURCE: Moderna, Inc.
`
`
`View source version on accesswire.com:
`
`https://www.accesswire.com/710243/Moderna-Announces-New-Supply-Contract-With-The-US-Government-For-
`An-Initial-66-Million-Doses-Of-A-Moderna-Bivalent-Covid-19-Booster-Vaccine-With-Options-For-US-Government-
`To-Purchase-Up-To-An-Additional-234-Million-Doses
`
`
`